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INTRODUCTION
Hexokinase 2 (HK2) is a rate-determining enzyme 
in aerobic glycolysis. HK2 is rarely expressed in normal 
tissues, except skeletal and cardiac muscle and adipose 
tissues [1]; however, it is frequently upregulated in tumor 
cells, leading to a phenomenon known as the Warburg Effect. 
In spite of frequent HK2 expression in various cancers [2], 
hepatocellular carcinomas (HCCs) exhibit heterogeneous 
expression of HK2 [3–5], which contributes to heterogeneous 
18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake in positron 
emission tomography (PET) scan [6, 7] and therefore reduces 
the clinical usefulness of 18F-FDG PET in HCCs [8, 9]. 
However, the regulation of HK2 expression in HCCs still 
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ABSTRACT
Hexokinase 2 (HK2) is a rate-determining enzyme in aerobic glycolysis, a process 
upregulated in tumor cells. HK2 expression is controlled by various transcription 
factors and epigenetic alterations and is heterogeneous in hepatocellular carcinomas 
(HCCs), though the cause of this heterogeneity is not known. DNA methylation in 
the HK2 promoter CpG island (HK2-CGI) and its surrounding regions (shore and 
shelf) has not previously been evaluated, but may provide clues about the regulation 
of HK2 expression. Here, we compared HK2 promoter methylation in HCCs and 
adjacent non-cancerous liver tissues using a HumanMethylation450 BeadChip 
array. We found that, while the HK2-CGI N-shore was hypomethylated, thereby 
enhancing HK2 expression, the HK2-CGI was itself hypermethylated in some HCCs. 
This hypermethylation suppressed HK2 expression by inhibiting interactions between 
HIF-1α and a hypoxia response element (HRE) located at  –234/–230. HCCs that 
were HK2negative and had distinct promoter CGI methylation were denoted as having a 
HK2-CGI methylation phenotype (HK2-CIMP), which was associated with poor 
clinical outcome. These findings indicate that HK2-CGI N-shore hypomethylation and 
HK2-CGI hypermethylation affect HK2 expression by influencing the interaction 
between HIF 1α and HRE. HK2-CGI hypermethylation induces HK2-CIMP and could 
represent a prognostic biomarker for HCC.
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remains elusive [10]. Defining the mechanisms underlying 
HK2 expression could give a clue about the heterogeneous 
expression of HK2 in HCCs. 
Various transcription factors and microRNAs are 
involved in the regulation of HK2 expression during cancer 
initiation and progression [11, 12]. Hypoxia-inducible 
factor-1α (HIF-1α) induces aggressive tumor phenotypes 
by regulating more than 60 target genes, including HK2 
[13]. Recently, HIF-1α was implicated in the indirect 
regulation of HK2 expression via the suppression of miR-
199a-5p [14]. Despite these findings, little is known about 
how HIF-1α directly regulates HK2 expression [15, 16].
CpG methylation, an epigenetic modification 
characterized by a substitution of cytosine-C5 with a 
methyl-cytosine in CpG dinucleotides, regulates gene 
transcription [17]. A recent report has suggested that 
gene expression is regulated by the alteration of CpG 
methylation in the promoter CpG island (CGI) shore (up 
to 2 kb upstream from CGI), rather than in the promoter 
CGI itself [18, 19]. Most CGIs in normal tissues remain 
largely unmethylated [20, 21], but unknown factors during 
cancer initiation and progression cause de novo methylation 
[22], perhaps by crosstalk between DNA methyltransferases 
(DNMTs) and histone methyltransferases (HMTs) [22, 23]. 
HK2 expression is regulated by CpG methylation [24, 25], 
but it is unclear whether these alterations occur in the HK2 
promoter CGI (referred to as HK2-CGI) or its shore. This 
knowledge may help to elucidate the precise molecular 
mechanism of HK2 expression.
In this study, to determine why HK2 is 
heterogeneously expressed in HCCs, we compared HK2 
promoter methylation in HCCs and adjacent non-cancerous 
liver tissues (Adj-NCLs) using the HumanMethylation450 
BeadChip (HM450) array. We evaluated how those 
methylation changes were influenced by DNMTs and HMTs 
using HCC cell lines with differential HK2 expression. 
We also identified a key regulatory region for expression 
of HK2 by dissecting the differentially methylated 
regions in the HK2 promoter and evaluated how these 
methylation changes influence HK2 expression. Finally, 
we demonstrated that HCCs with specific and significant 
methylation changes could be regarded as a phenotypic 
HCCs subgroup.
RESULTS
HK2-CGI hypermethylation in HK2negative HCCs
To identify the mechanism underlying HK2 
expression, we assessed HCCs and Adj-NCLs for 
differences in CpG methylation in the HK2 promoter. We 
initially performed bisulfite sequencing and pyrosequencing. 
However, the dense CpGs in the HK2-CGI region made it 
difficult to analyze the methylation status of that region. 
Thus, we conducted a comparative methylation analysis 
using the HM450 array on 24 HCCs and 18 Adj-NCLs. This 
analysis revealed global hypomethylation (Supplementary 
Figure S1A) in the HCCs, which discriminated them from 
Adj-NCLs in an unsupervised hierarchical clustering 
analysis (14/24, 58.3%; Supplementary Figure S1B). The 
branch lengths were longer in HCCs than in Adj-NCLs, 
indicating that HCCs are more heterogeneously methylated 
(Supplementary Figure S1B).
We also observed an altered methylation profile in 
and around the HK2-CGI (Figure 1A). In Adj-NCLs, most 
regions of the HK2 promoter were densely methylated, 
while HCC tissues were hypomethylated, particularly in the 
HK2-CGI N-shore (Figure 1A upper panel). On the contrary, 
the HK2-CGI was sparsely methylated in Adj-NCLs, while 
the -40 CpG site in the HK2-CGI was hypermethylated in 
HCCs (P = 0.0372, Figure 1A upper panel).
Because altered methylation in the HK2-CGI and 
its N-shore should correlate with the regulation of HK2 
expression, we investigated the relationship of methylation 
status of HK2 promoter with HK2 protein expression 
(Figure 1B upper panel). Interestingly, we observed 
-40 CpG hypermethylation in some HK2negative HCCs; 
the -25 CpG was hypermethylated in these cells as well 
(P = 0.0324, Figure 1B lower panel and Supplementary 
Figure S2A). This HK2-CGI hypermethylation profile 
was not found in any other HCCs tested, thus we grouped 
this subset of HCCs by their CGI methylation phenotype, 
naming them HK2-CIMP (Figure 1B and Supplementary 
Figure S2B). The HK2-CGI N-shore was hypomethylated 
in the HK2positive and HK2negative-non-CIMP HCCs, but there 
were no significant differences between these two groups 
(Figure 1B lower panel). In this same region, HK2-CIMP 
HCCs showed the most robust hypomethylation in the 
N-shore (Figure 1B lower panel). Taken together, these 
data indicate that most regions of the HK2 promoter are 
relatively hypomethylated in HCCs compared to Adj- NCL, 
which is consistent with previous reports [26, 27]. 
However, the HK2-CGI was hypermethylated in a subset 
of cells, the HK2-CIMP HCCs, which do not express HK2 
protein.
The correlation of HK2 suppression and HK2-
CGI hypermethylation
To determine whether HK2-CGI hypermethylation 
was responsible for HK2 suppression in HK2-CIMP HCCs, 
we examined HK2 protein expression in the HCC cell lines: 
Hep3B, SNU449, and SNU475. Hep3B cells expressed HK2 
more abundantly than did SNU475 cells, while SNU449 
cells did not express detectable levels of HK2 (Figure 2A 
upper panel). These results were consistent with RT-PCR 
results from the same cell lines (Figure 2A lower panel). 
Next, we assessed the methylation status of HK2 in these 
cell lines using the HM450 array. Hep3B and SNU475 cells 
had a hypomethylated N-shore of the HK2-CGI, consistent 
with results from the HK2positive HCC tissues tested. The 
HK2-CGI of those cells was not methylated, while that 
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of SNU449 cells was densely methylated (Figure 2B). 
We conducted bisulfite sequencing to confirm the 
methylation status of the HK2-CGI. Consistent with the 
HM450 array data, the HK2-CGI of SNU449 cells was 
densely methylated, while in SNU475 and HepB3 cells it 
was not (Figure 2C).
To verify the factors that contribute to 
hypermethylation in the HK2-CGI, we measured the 
protein expression of DNA methyltransferases (DNMTs) 
and histone methyltransferases (HMTs) in each cell line 
using immunoblots. We observed slight differences in 
DNMT1 expression between the cell lines; however, 
DNMT3A and DNMT3B were more abundant in SNU449 
cells than in Hep3B and SNU475 cells (Figure 2D upper 
panel). HMTs, such as Enhancer of Zeste 2 (EZH2) and 
Euchromatic histone-lysine N-methyltransferase 2 (EHMT2 
Figure 1: Two different alterations of CpG DNA methylation in the HK2 promoter: hypomethylation at the HK2-
CGI N-shore and hypermethylation at the HK2-CGI observed only in HK2negative HK2-CIMP HCCs. (A) A comparison 
of HK2 promoter methylation status between HCC and Adj-NCL tissues. The HK2-CGI located at the range of -388 to +500 bp from 
the transcriptional start site (TSS: +1) was predicted by Methprimer (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi, lower 
panel). (B) The methylation status of the HK2 promoter according to HK2 expression in HCC tissues. HK2positive or HK2negative was defined 
by immunoblot. The β-values of CpGs in the HK2 promoter were plotted. Two vertically dashed line indicted the borders of the HK2-CGI. 
Values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant.
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or G9A), are associated with the recruitment of DNMT3s 
[22]. Expression of both of these proteins was increased in 
SNU449 cells (Figure 2D lower panel).
Furthermore, we evaluated histone lysine 
methylation status such as tri-methylation of lysine 4, 
lysine 9, and lysine 27 on histone 3 (H3K4me3, 
H3K9me3, and H3K27me3, respectively) to determine 
the status of chromatin modifications near the HK2 
gene. The histone lysine methylation status of SNU475 
cells indicated active chromatin (H3K4me3 high, 
H3K9me3 low, and H3K27me3 low) in the HK2-
CGI, while that of SNU449 cells represented a poised 
chromatin status (H3K4me3 high and H2K27me3 high) 
at the same region (Figure 2E). Moreover, the histone 
lysine methylation status of the HK2-CGI N-shore was 
similar to that of the HK2-CGI (Figure 2E). These 
data suggest that SNU449 cells are representative of 
HK2-CIMP HCCs with respect to HK2 expression and 
methylation status of the HK2 promoter. The presence of 
H3K9me3 and H3K27me3 and the increased expression 
of DNMT3s, EZH2, and G9A suggest that HK2-CGI 
hypermethylation may result from crosstalk between 
DNMT3s and HMTs to alter HK2-CGI methylation and 
HK2 expression.
Figure 2: Hypermethylation of the HK2-CGI caused by the crosstalk of DNMTs and HMTs suppresses HK2 expression 
in HCC cell lines. (A) HK2 protein expression in HCC cell lines (Hep3B, SNU475, and SNU449 cells) was evaluated by immunoblot 
and RT-PCR. (B) Methylation status of HK2 promoter among HCC cell lines. The HK2-CGI is indicated by dashed lines. (C) Bisulfite 
sequencing of the HK2-CGI in Hep3B, SNU475, and SNU449 cells. Each circle indicates an individual CpG site. An individual row 
represents a single clone. The open and closed circles denote unmethylated and methylated CpG sites, respectively. (D) DNMTs (DNMT1, 
DNMT3A, and DNMT3B) and HMTs (EZH2 and G9A) were evaluated in HCC cell lines by immunoblot. (E) The chromatin status of 
indicated cell lines was evaluated by H3K4me3- , H3K9me3-, and H3K27me3-ChIP assay.
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Identification of the -234/-230 HRE in the HK2 
promoter
Although our observations suggested that HK2 
expression was largely regulated by epigenetic alterations, 
we sought to identify any cis-acting regions and 
corresponding trans-acting elements that also contribute 
to the regulation of HK2 expression. A series of HK2 
promoter luciferase deletion constructs were generated to 
map the promoter regions that regulate HK2 expression 
(Figure 3A upper panel). The luciferase activity of most 
constructs was increased in response to hypoxic stimuli. 
Interestingly, the -175 construct had decreased luciferase 
activity (Figure 3A lower panel), suggesting that the 
promoter region between −305 to −175 is an important 
regulatory region. Thus, additional luciferase constructs 
were generated using the Transcriptional Element Search 
System (http://www.cbil.upenn.edu/tess) (Figure 3B upper 
panel). When the luciferase activity of each construct 
was analyzed in Hep3B cells, activity was profoundly 
decreased in the −255 and −175 constructs under hypoxic 
conditions (Figure 3B lower panel). Further analysis 
suggested putative Sp1 and HIF-1α binding sites in −270 
and −234 region.
We therefore performed luciferase assays with 
three kinds of −270/−234 site-specific mutants (MW, 
WM, and MM; Figure 3C upper panel) in Sp1 and/or 
HIF-1α binding sites. Relative decreases of luciferase 
activity among mutants were observed under normoxic 
conditions. Luciferase activity of the HRE mutant (WM) 
decreased to baseline under hypoxic conditions (Figure 
3C lower panel). To determine whether the −234/−230 
putative HRE acts as a key regulatory region for HK2 
expression, the −234/−230 HRE was mutated in the 
−965 construct (−965M). Luciferase activity of −965M 
was decreased to baseline under hypoxic conditions 
(Figure 3D left panel). Moreover, luciferase activity of 
−965W was decreased by silencing HIF-1α using RNA 
interference (Figure 3D right panel).
Next, we tested whether HIF-1α interacts with 
this HRE. We immunoprecipitated nuclear extracts of 
hypoxia-treated Hep3B cells with the anti-HIF-1α antibody 
(Ab) and observed a strong enrichment of the HK2-CGI 
region (−302/–114 PCR product) (Figure 3E). Finally, 
we confirmed a direct interaction between HIF-1α and 
−234/−230 HRE using electrophoretic mobility shift assays 
(EMSAs). The −234/−230 HRE consensus sequence probe 
showed a specific interaction with the nuclear extract, 
while its mutant probe did not (Figure 3F). Moreover, 
cold −234/−230 HRE probe inhibited the mobility shift of 
the −234/−230 HRE consensus sequence probe in a dose-
dependent manner. The same inhibition was observed 
when anti-HIF-1α Ab was applied (Figure 3F). Taken 
together, these data show that HK2 expression is regulated 
by an interaction between HIF-1α and the −234/−230 HRE 
in the HK2-CGI.
Induced hypomethylation of the HRE in the 
HK2-CGI allows HIF-1α binding and HK2 
expression
We next investigated the influence of HK2-CGI 
methylation on HK2 expression under conditions where 
the interaction between HIF-1α and newly defined -234/-
230 HRE was blocked. In SNU475 cells, which show 
hypomethylation in the HK2-CGI, HK2 expression was 
observed under normoxic conditions and increased by 
hypoxic conditions. In contrast, SNU449 cells, which 
exhibit hypermethylation in that region, did not express 
HK2, even under hypoxic conditions (Figure 4A). The 
increase in HK2 expression in SNU475 cells was reversed 
by si-HIF1A-mediated silencing (Figure 4B).
To demonstrate that HK2-CGI hypermethylation is 
a prerequisite for HK2 suppression, we evaluated whether 
5-Aza-CdR-induced hypomethylation could reverse HK2 
expression. Treatment of SNU475 and SNU449 cells with 
5-Aza-CdR caused hypomethylation of the HK2 promoter 
(Figure 4C). Because SNU475 cells were originally 
hypomethylated on the −234/−230 HRE of the HK2-CGI, 
5-Aza-CdR did not change HK2 expression (Figure 4D left 
panel). In contrast, SNU449 cells expressed HK2 following 
treatment with 5-Aza-CdR and hypoxic stimuli (Figure 4D 
right panel). This observation was the result of increased 
binding of HIF-1α to the −234/−230 HRE in the HK2 
promoter (Figure 4E). All together, these findings indicate 
that the HK2-CGI hypermethylation suppresses HK2 
expression via inhibition of the interaction between HIF-1α 
and −234/−230 HRE.
HK2-CIMP, a distinct subgroup in HCCs
HK2-CIMP HCCs exhibited a different methylation 
pattern in the HK2-CGI (Figure 5A). Because CpG 
methylation was not altered at a single gene level, as 
visualized by unsupervised hierarchical clustering analysis 
(Supplementary Figure S1), we further analyzed CpG sites 
according to HK2 expression. Most HK2-CIMP HCCs 
exhibited divergent methylation patterns from other HCCs 
and clustered together (4/5, 80%; Figure 5B). Furthermore, 
when we sorted and analyzed the CGIs located within the 
promoter locus by unsupervised hierarchical clustering, 
we found 289 CpG sites with differential methylation, 
which enabled us to discriminate HK2-CIMP HCCs from 
other HCCs (Figure 5C). 
HK2 expression in glioblastoma multiforme (GBM) 
tumors was associated with reduced overall survival 
(OS) of patients [28]. Thus, we examined OS in our set 
of HCCs according to HK2 expression. Our data did not 
show a difference in OS between the HK2 upper 25th 
percentile group (HK2 upper 25; n = 8) and the HK2 lower 
75th percentile group (HK2 lower 75; n = 24) (P = 0.192, 
Figure 5D left panel). We tested whether this result was 
due the grouping of HK2-CIMP HCCs into the HK2 lower 
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Figure 3: Identification of -234/-230 HRE, a key region in the HK2 promoter regulated by methylation. (A) The promoter 
activity of HK2 promoter-deleted luciferase constructs was evaluated in HCC cell lines under normoxic and hypoxic conditions. Luciferase 
activity of all test constructs was normalized to that of the null construct. The relative luciferase activity was plotted as the percentage of 
the -1921 construct under normoxic or hypoxic conditions. (B) The promoter activity of HK2 promoter-deleted luciferase constructs under 
normoxic or hypoxic conditions using Hep3B cells (rectangle; putative HRE, circle; putative Sp1-binding site). (C) The HK2 promoter 
site-specific mutant luciferase constructs for putative HIF-1α and Sp1 binding sites were constructed as described in the upper panel. The 
promoter activity of each mutant construct under normoxic or hypoxic conditions is shown as the luciferase activity relative to the -175 
construct (red closed circle; putative Sp1-binding site, green open rectangle; putative HRE). (D) The luciferase activity of the -965W and 
-965M under normoxic (N) or hypoxic (H) conditions. (E) The interaction between the -234/-230 HRE and HIF-1α was evaluated by 
ChIP assay. Sp1 was used as a positive control. The -302/-114 region and a non-relevant region (480/792) designed as shown in the upper 
panel were amplified by PCR. The specific interaction was plotted as the percentage of the input in the lower panel. (F) EMSA experiment 
involving the -234/-230 HRE and the mutant version (HREm) on the human HK2 promoter. The oligonucleotides shown in the upper panel 
were labeled and incubated with nuclear extracts from Hep3B cells. NS, non-specific bands.
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75 group. When HK2-CIMP HCCs were plotted as a group 
in a Kaplan-Meier survival analysis, they displayed a similar 
OS to that of the HK2 upper 25 group. Moreover, the P 
value was reduced by removing the HK2-CIMP HCCs from 
the HK2 lower 75 group (P = 0.144, Figure 5D right panel). 
These findings suggest that HK2-CIMP HCCs should be 
regarded as a distinct subgroup in HCCs.
DISCUSSION
HK2 expression offers an advantage to cancer 
cells by increasing aerobic glycolysis, resulting in an 
altered metabolic state with an anti-apoptotic effect [2]. 
Despite this survival benefit, HCCs are heterogeneous 
in their expression of HK2 [3–5]. Here, we demonstrated 
that the heterogeneous expression of HK2 was caused 
by altered CpG DNA methylation at the HK2 promoter 
(summarized in Figure 6). In agreement with a recent 
study of hypomethylation in the promoter CGI N-shore 
[23], we report, for the first time, the HK2-CGI N-shore 
hypomethylation shows a strong association with HK2 
expression in HCCs. Moreover, despite severe HK2-CGI 
N-shore hypomethylation, HK2-CGI hypermethylation in 
HK2-CIMP HCCs merely abolished HK2 expression. This 
observation was the result of a blocked HIF-1α binding 
site, −234/−230 HRE, a newly defined key regulatory 
region in the HK2 promoter. Finally, the correlation of 
HK2- CIMP with clinical outcome suggests that HK2- CIMP 
Figure 4: The induction of HK2 expression in HK2negative SNU449 cells by treatment with 5-Aza-CdR and hypoxia. 
(A) Hypoxia-mediated HK2 expression. (B) The suppression of HK2 expression by HIF-1α silencing. (C) The methylation status of the 
HK2 promoter CpGs plotted for the 5-Aza-CdR-treated SNU475 cells and SNU449 cells. The difference in methylation frequency between 
5-Aza-CdR-treated cells and untreated cells is shown in each lower panel. (D) The induction of HK2 expression in SNU475 and SNU449 
cells by treatment with 5-Aza-CdR for 2 d, followed by hypoxic stimuli for 1 d. In all experiments, the expression of HIF-1α and HK2 
were evaluated by immunoblot. (E) The interaction between the -234/-230 HRE and HIF-1α following 5-Aza-CdR treatment was evaluated 
using a ChIP assay.
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Figure 5: HK2-CIMP, a distinct subgroup of HCCs. (A) The methylation status of HK2-CGI and its N-shore, according to HK2 
expression. Unsupervised hierarchical clustering of (B) the top 1,417 significantly differentially methylated CpG sites between 13 HK2positive 
and 10 HK2negative HCCs and (C) further selected 289 CpG sites located in the promoter CGI which corresponds to TSS1500, TSS200, 
5′UTR and 1st Exon. (D) Overall survival after surgery was compared using Kaplan-Meier analysis (Left panel) between the HK2 upper 
25th percentile (n = 8) and HK2 lower 75th percentile (n = 24), and (Right panel) between HK2 upper 25th percentile (n = 8) and HK2 lower 
75th percentile except HK2-CIMP HCCs (n = 19), which were plotted separately as an HK2-CIMP group (n = 5).
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HCCs could be regarded as a distinct subgroup of HCCs, 
and HK2-CGI hypermethylation, represented by -40 
CpG hypermethylation, could be used as a biomarker for 
predicting prognosis of HCC patients.
The effects of aberrant DNA methylation changes 
on gene expression have been examined in many cancers, 
including HCCs [29, 30]. Those studies focused on the 
differences of mean values of CpG DNA methylation 
in promoter regions only. Thus, the correlation between 
methylation changes and gene expression was weaker 
than expected. However, a recent report on aberrant DNA 
methylation in HCCs investigated methylation changes 
according to genomic locations, such as the promoter CGI 
and its surrounding regions (shore and shelf) [31]. This 
study revealed that CpG DNA methylation changes were 
more frequently observed in the promoter CGI shore than 
in the promoter CGI [31], which may result in altered gene 
expression [23].
Figure 6: A model for opposing regulatory mechanisms of HK2 expression, according to the methylation status of 
the HK2-CGI and its N-shore. In normal liver cells, the HK2 promoter is initially hypermethylated (closed circles) at the HK2-CGI 
N-shore and hypomethylated (open circles) at the HK2-CGI. In HCCs with HK2 expression, the HK2-CGI N-shore is progressively 
hypomethylated, while the HK2-CGI remains unmethylated, as evidenced by active chromatin marks (H3K4me3 high, H3K9me3 low, 
and H3K27me3 low). These modifications enable HIF-1α to access the HRE in the HK2-CGI, resulting in HK2 expression. In HK2-CIMP 
HCCs, the HK2-CGI is methylated and is accompanied by the poised status of chromatin (H3K4me3 high and H3K27me3 high), which 
inhibits HIF-1α from binding to the HRE in the HK2-CGI, resulting in HK2 suppression. The dashed circles, triangles, and stars denote that 
the methylation status of H3 lysine was not determined.
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Our observations of global hypomethylation and 
HK2- CGI N-shore hypomethylation are consistent with 
previous studies [29–31], but the HK2-CGI hypermethylation 
that we observed in HK2-CIMP HCCs has not been 
previously reported. Moreover, to our knowledge, this 
is the first report of such opposing alterations in the same 
gene. We observed HK2-CGI hypermethylation only in 
HK2negative HK2-CIMP HCCs and in SNU449 cells, which 
might be explained by a model of de novo methylation in 
cancer [22]. In normal hepatocytes, the HK2-CGI remained 
largely unmethylated, which might be mediated by polycomb 
repressive complex 2 (PRC2) as observed in other genes 
[22, 32]. However, in HCCs, unknown factors may cause 
an increase in EZH2 and G9A expression, resulting in the 
enrichment of H3K27me3 and H3K9me3. Moreover, 
the increase in EZH2 or G9A might alter the equilibrium 
of PRC2 at the HK2-CGI, which enables DNMT3s to 
bind to EZH2 or G9A via SET domain and cause de novo 
methylation. The increased expression of EZH2 and G9A 
and the enrichment of H3K27me3 and H3K9me3 that we 
observed in SNU449 cells supports this hypothesis.
When CpG DNA methylation was analyzed according 
to HK2 expression, most HK2-CIMP HCCs were grouped 
together. Furthermore, when this analysis was restricted 
to CpGs in the promoter CGI, all HK2-CIMP HCCs show 
a similar methylation pattern. Thus, HK2-CIMP HCCs 
might represent a subgroup having a de novo methylation-
prone phenotype. Therefore, HK2-CGI methylation could 
be applied as a biomarker for an epigenetic subtyping to 
suggest potential prognosis of HCC. Our newly found 289 
hypermethylated CGIs suggest the molecular mechanism 
of de novo methylation, thus, we are currently investigating 
this de novo methylation using SNU449 cells.
We also defined a cis-acting region −234/−240 HRE 
and its trans-acting element, HIF-1α. Moreover, 5-Aza-
CdR-mediated hypomethylation showed that HK2-CGI 
hypermethylation could directly suppress HK2 expression. 
However, in some HK2negative non-CIMP HCCs, HK2 was 
not expressed in spite of the hypomethylation in both HK2-
CGI and its N-shore. According to our data, the meaning 
of HK2-CGI hypermethylation could be different from that 
of HK2-CGI N-shore hypomethylation. When HK2-CGI 
hypermethylation is present (called HK2-CIMP), the HK2-
CGI hypermethylation is a critical determining factor for 
HK2 expression. However, when HK2-CGI methylation 
is absent, the regulation of HK2 expression was not only 
influenced by the methylation status of HK2-CGI N-shore, 
but also influenced by other factors such as the level of 
HIF-1α expression, and miRNA, which must be further 
evaluated. To understand the precise regulation of HK2 
expression, we need more understanding of the crosstalk 
among transcription factors, CpG DNA methylation, and 
chromatin status. For instance, in normal hepatocytes, HK2 
expression was suppressed despite the absence of HK2-
CGI methylation. This observation may be due to repressed 
chromatin status or polycomb proteins, which keep CGIs 
unmethylated by inhibiting de novo methylation [22]. Thus, 
we need to continue to investigate the epigenetic status of 
the HK2 promoter and the detailed interactions of related 
proteins, which could reveal some factors that cause de 
novo methylation in promoter CGIs.
Some limitations to this study should be addressed. 
First, the correlation of HK2-CIMP and HCC progression 
was not fully evaluated. A recent report showed that 
HK2-suppressed GBM tumors had more aggressive and 
metastatic features [28]; however, our results on OS were 
not significant. These limitations could be overcome through 
the evaluation with larger sample size of HK2-CIMP HCCs. 
Second, we did not fully address the molecular mechanism 
of hypomethylation observed in the HK2-CGI N-shore, 
which might share a mechanism with the HIF1A promoter 
hypomethylation [33]. Ten-Eleven Translocation 1 (TET1) 
regulates the expression of HIF-1α target genes by inducing 
CpG hypomethylation near an HRE [34]. Interestingly, 
TET1 interacts with PRC2 [35]. Thus, we could 
hypothesize that the interactions between TET1, PRC2, 
and the HK2- CGI lead to hypomethylation in the HK2-CGI 
N-shore. Further evaluation and testing of this hypothesis 
may lead to a generalized mechanism of regulation for other 
genes that have CGIs in their promoters. Finally, we did 
not examine the interaction between the HK2 promoter and 
Sp1. We observed a decrease of luciferase activity between 
the −268 and −255 constructs, as reported previously [36], 
and our ChIP assay data revealed an interaction between 
Sp1 and this region. Recently, an interaction between Sp1 
and HIF- 1α was reported [37, 38]. Thus, further studies 
may reveal an interaction between Sp1 and HIF-1α in the 
regulation of HK2 expression. 
In conclusion, we identified two oppositional 
alterations in the HK2 promoter that regulate HK2 
expression. The first alteration is hypomethylation in the 
HK2-CGI N-shore, which increases HK2 expression. The 
second alteration is hypermethylation in the HK2-CGI, 
which contributes to HK2 suppression via inhibition of 
the interaction between −234/−230 HRE and HIF-1α. The 
latter alteration was observed only in HK2-CIMP HCC 
cells. HK2-CIMP HCCs represent a subgroup of cells with 
hypermethylated CGI in the promoter and a poor clinical 
outcome. Thus, HK2-CGI methylation status could serve as 
a prognostic biomarker.
MATERIALS AND METHODS
Patients and tissue samples
Among the patients who underwent a liver 
resection between 2009 and 2010 at Severance Hospital, 
Yonsei University College of Medicine, Seoul, Korea, 
the clinical and histological data were analyzed from 
32 HCC patients whose tissue samples were available. 
Upon authorization from the Institutional Review Board 
of Severance Hospital (4-2013-0789), snap-frozen tissue 
samples were provided by the Gene Bank in Severance 
Hospital.
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Cell culture
Hep3B, SNU449, and SNU475 cells were obtained 
from the Korean Cell Line Bank (Seoul, Korea) and cultured 
in RPMI-1640 or Modified Eagle Medium supplemented 
with 10% FBS (HyClone, Tauranga, New Zealand) at 37°C 
in a humidified CO2 incubator. Hypoxia experiments were 
conducted in 1% O2, 5% CO2, and 94% N2 overnight. Cells 
were treated with 5-Aza-2-deoxycytidine (5-Aza-CdR; 
Sigma-Aldrich, St. Louis, MO, USA) in 6-well plates for 
72 h with freshly prepared 5-Aza-CdR.
HumanMethylation450 BeadChip array
Genomic DNA was extracted from human liver 
tissues and HCC cell lines (Hep3B, SNU475 and SNU449 
cells) using QIAGEN DNA miniprep kits (Valencia, CA, 
USA) according to the manufacturer’s instructions. Then 
DNA was modified using EZ DNA methylation-direct 
kits (Zymo Research, Irvine, CA, USA). The HM450 
BeadChip array (Illumina, San Diego, CA, USA) analysis 
was conducted according to the manufacturer’s instructions. 
Methylation levels were reported as β-values, with a range 
from 0 to 1. All HM450 arrays were processed by LAS Inc. 
(Daejeon, Korea).
Bisulfite sequencing
Nested PCRs were performed with bisulfite-treated 
genomic DNA from Hep3B, SNU475 or SNU449 cells 
using the primers described in Supplementary Table S1. 
The resulting amplification pools were cloned into the 
pCR II vector using a TA cloning kit (Invitrogen Life 
Technologies, Carlsbad, CA, USA) and sequenced using 
T7 and SP6 primers.
Immunoblot analysis
The following antibodies (Abs) were used: anti-HK2 
(sc-6521; Santa Cruz, Dallas, TX, USA), anti-DNMT1 
(A300-041A; Bethyl Laboratories, Montgomery, TX, USA), 
anti-DNMT3A (LS-C167495; LifeSpan BioSciences, 
Seattle, WA, USA), anti-DNMT3B (LS-C128621; LifeSpan 
BioSciences), anti-G9A (A300-933A; Bethyl Laboratories), 
anti-EZH2 (LS-C167874; LifeSpan BioSciences), anti-HIF-
1α (A300-286A; Bethyl Laboratories), and anti-β-actin 
(AC-15; Sigma-Aldrich).
Chromatin immunoprecipitation (ChIP) assay
Cells were fixed with 1% formaldehyde (Sigma-
Aldrich) for 20 min. Fixation was quenched with 
0.125 M glycine for 10 min. Cells were harvested and 
lysed, and nuclei were sonicated using a Bioruptor 
(COSMO Bio, Tokyo, Japan). Chromatin samples were 
immunoprecipitated with anti-H3 (ab1791; Abcam, 
Cambridge, UK), anti-H3K4me3 (ab8580; Abcam), anti-
H3K9me3 (ab8898; Abcam), anti-H3K27me3 (ab6002; 
Abcam), anti-HIF-1α, anti-Sp1 (EMD Millipore, 
Temecula, CA, USA) and control IgG (sc-2027; Santa 
Cruz) at 4°C overnight, and then proteins were harvested 
with mouse anti-IgG Ab linked to magnetic protein 
A&G beads (Dynal, Lake Success, NY, USA). Immune 
complexes were disrupted, and 2 μl DNA dissolved in 50 
μl water was used as template for PCR with the primers 
described in Supplementary Table S1.
Promoter luciferase assay
All luciferase reporter constructs were generated 
by PCR using the described primer sets (Supplementary 
Table S2) and the pGL3-basic luciferase reporter vector 
(Promega, Madison, WI, USA). All mutant constructs 
were generated using a QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, Santa Clara, CA, USA). 
Cells were transfected with luciferase reporter constructs 
including 50 ng pRL-SV40 as a transfection control using 
Lipofectamine 2000 (Invitrogen Life Technologies). DNA 
quantities equimolar to 2 μg of the -1921 human HK2 
promoter construct were used for all luciferase reporter 
constructs. The luciferase activities were measured using 
the Dual-Luciferase™ Reporter Assay System (Promega) 
and a VICTORTM X4 luminometer (PerkinElmer, 
Waltham, MA, USA), and were analyzed based on the 
ratio of Firefly (luciferase constructs): Renilla (pRL-SV40 
vector) and normalized to the cell number and transfection 
efficiency.
Electrophoretic mobility shift assay (EMSA)
EMSAs were conducted with nuclear extracts from 
Hep3B cells as described previously [39]. Double stranded 
−234/−230 HRE or −234/−230 HRE mutant (−234/−230 
HREm) probes were labeled with [γ-32P] ATP using T4 
polynucleotide kinase (New England BioLabs, Ipswich, 
MA, USA) and purified with a ProberTM column (iNtRON, 
Gyeonggi-do, Korea). The binding reactions were completed 
with or without competitors, including −234/−230 HRE 
or −234/−230 HREm cold probes, and anti-HIF-1α Ab. 
Protein-DNA complexes were separated from the free probe 
by electrophoresis on a 5% polyacrylamide gel in 0.25× 
TBE buffer. After drying, gels were exposed to a Phosphor 
Imager FLA 7000 (FUJIFILM, Tokyo, Japan) at −70°C 
overnight.
Small interfering RNA (siRNA)
The siRNAs targeting HIF1A (NM_001530) 
(Supplementary Table S3, Integrated DNA Technologies, 
Coralville, IA, USA) were transfected using Lipofectamine 
RNAiMAX (Invitrogen Life Technologies) according to the 
manufacturer’s protocol.
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Statistical analysis
For statistical analyses, unpaired Student’s t-tests, 
Pearson’s correlation tests, and Kaplan-Meier analyses 
were applied as appropriate using SPSS 20 for Windows 
(IBM, Armonk, NY, USA). All in vitro experiments 
were performed at least three times. Values represent the 
mean ± SEM. For all experiments, statistical significance is 
denoted accordingly: *P < 0.05, **P < 0.01, ***P < 0.001.
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